Avidity-Partners-Management-Lp

Filing Details

13F-HR2025-03-31
Report Date
2025-03-31
Filing Date
2025-05-15
Total Holdings
64
Total Value
488981882
Accession Number
0001791827-25-000005
Form Type
13F-HR
Manager Name
Avidity-Partners-Management-Lp
Data Enrichment
97% identified
62 identified2 unidentified

Holdings

64 positions • $489.0M total value
Manager:
Search and click to pin securities to the top
Page 1 of 4
BOSTON SCIENTIFIC CORP
Shares:336.0K
Value:$33.9M
% of Portfolio:6.9% ($33.9M/$489.0M)
Dianthus Therapeutics, Inc. /DE/
Shares:1.7M
Value:$31.2M
% of Portfolio:6.4% ($31.2M/$489.0M)
UNITEDHEALTH GROUP INC
Shares:50.5K
Value:$26.4M
% of Portfolio:5.4% ($26.4M/$489.0M)
CG Oncology, Inc.
Shares:980.9K
Value:$24.0M
% of Portfolio:4.9% ($24.0M/$489.0M)
HUMANA INC
Shares:80.0K
Value:$21.2M
% of Portfolio:4.3% ($21.2M/$489.0M)
Natera, Inc.
Shares:119.2K
Value:$16.9M
% of Portfolio:3.4% ($16.9M/$489.0M)
REGENERON PHARMACEUTICALS, INC.
Shares:25.4K
Value:$16.1M
% of Portfolio:3.3% ($16.1M/$489.0M)
EXACT SCIENCES CORP
Shares:353.0K
Value:$15.3M
% of Portfolio:3.1% ($15.3M/$489.0M)
Beam Therapeutics Inc.
Shares:709.5K
Value:$13.9M
% of Portfolio:2.8% ($13.9M/$489.0M)
GLAUKOS Corp
Shares:134.0K
Value:$13.2M
% of Portfolio:2.7% ($13.2M/$489.0M)
DEXCOM INC
Shares:180.0K
Value:$12.3M
% of Portfolio:2.5% ($12.3M/$489.0M)
Ultragenyx Pharmaceutical Inc.
Shares:322.1K
Value:$11.7M
% of Portfolio:2.4% ($11.7M/$489.0M)
03073E105
Shares:39.3K
Value:$10.9M
% of Portfolio:2.2% ($10.9M/$489.0M)
Jazz Pharmaceuticals plc
Shares:80.0K
Value:$9.9M
% of Portfolio:2.0% ($9.9M/$489.0M)
TENET HEALTHCARE CORP
Shares:72.0K
Value:$9.7M
% of Portfolio:2.0% ($9.7M/$489.0M)
NEUROCRINE BIOSCIENCES INC
Shares:85.7K
Value:$9.5M
% of Portfolio:1.9% ($9.5M/$489.0M)
DANAHER CORP /DE/
Shares:44.5K
Value:$9.1M
% of Portfolio:1.9% ($9.1M/$489.0M)
Axsome Therapeutics, Inc.
Shares:77.0K
Value:$9.0M
% of Portfolio:1.8% ($9.0M/$489.0M)
GENMAB A/S
Shares:433.1K
Value:$8.5M
% of Portfolio:1.7% ($8.5M/$489.0M)
INSMED Inc
Shares:107.0K
Value:$8.2M
% of Portfolio:1.7% ($8.2M/$489.0M)